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Abstract  
BACKGROUND: Cytokines including Interleukin-5 play a key role in orchestrating the chronic 
inflammation of asthma. We aimed to determine the level of serum IL-5 in partly controlled atopic 
asthma in children and to assess the effect of different therapies on their levels.  
METHODS: The study included 40 children aged 6-12 years with partly controlled asthma. Cases 
were randomly divided into two groups; group ‘A’ receiving Leukotriene modifiers and group ‘B’ 
receiving inhaled corticosteroids; each for two months. They were compared to 20 healthy non-
asthmatic, matched controls. Serum IL-5 was measured for cases on the first visit and two months 
after therapy. Absolute eosinophilic count and serum Ig-E were determined. Pulmonary function 
testing was performed using spirometer at the beginning and two months after regular therapy.  
RESULTS: Serum Interleukin-5 was significantly increased in asthmatic children during 
exacerbation and was significantly decreased after treatment. ROC curve analysis showed 
significant difference of IgE and PEFR after treatment with leukotriene modifier only.  
CONCLUSION: Serum IL-5 seems to have a role in asthma pathogenesis. Efficiency of the two 
therapies (ICs & LTA) was similar in this group of patients. Both treatments led to significant decline 
in serum IL-5, IgE levels and eosinophilic count.   
 
 
 
 
 
 
 
 
Introduction 
Asthma is a chronic inflammation of the 
airways with reversible episodes of obstruction, 
caused by an increased reaction of the airways to 
various stimuli [1]. In 2009, Zedan et al [2] found that 
the prevalence of asthma among school children in 
the Nile Delta was 7.7 %.  GINA guidelines (2011) 
provide classification of asthma by level of control into 
three categories (controlled, partly controlled and 
uncontrolled asthma), based on daytime symptoms, 
nocturnal symptoms, limitation of activity, need to 
quick-relief medicine, peak flow rate, and incidence of 
exacerbation per year [3]. 
Accumulating evidence indicates that 
classical Th2 cell derived cytokines (e.g. IL-3, IL-4, IL-
5, IL-9, IL-13 and GM-CSF) together with eotaxin play 
critical roles in the induction of airway hyper reactivity 
and the development of chronic airway wall 
remodeling [4]. IL-5 acts as a mediator of activation of 
eosinophils, influencing adhesion, membrane receptor 
expression, chemotaxis, and mediator synthesis. 
Airway eosinophilia has been related to bronchial 
hyper reactivity, asthma symptoms, and airway 
narrowing in subjects with asthma [5]. 
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  The aim of the present study was to 
determine the level of serum IL-5 in partly controlled 
atopic asthma in children during exacerbation and 
remission of asthma attacks, and to assess its 
possible role in asthma pathogenesis for these 
children. We aimed also to compare the therapeutic 
effect of LTA and ICS in partly controlled asthmatic 
Egyptian children. 
 
Methods 
The study included 40 asthmatic children 
aged 6-12 years (7.5 1.8). They were diagnosed as 
partly controlled asthma according to GINA Guidelines 
[3] and were attending chest and allergic out patient 
clinic of Children's Hospital, Cairo University for 
receiving treatment in the period from June 2010 to 
January 2011.  Another 20 healthy children of the 
same age and sex were recruited as controls. All 
cases had an established clinical history of asthma 
and positive family history of atopy and were not 
receiving treatment in the previous month. Patients 
with history of chronic lung diseases or non-atopic 
asthmatic children or those presented with stridor 
were excluded from the study. All the participant's 
guardians had signed written form consent after 
explaining the steps and aim of the study to them. 
Ethical committee of NRC has approved the study. 
  
Complete History 
Details about respiratory symptoms (age of 
onset, duration of asthma, frequency, diurnal 
variation, precipitating factors, diagnosis, need for oral 
steroid and frequency of use). 
 
Physical Examination 
Anthropometric measurements (height, 
weight), complete system examination to exclude 
other diseases, and chest examination to assess 
respiratory condition were performed. Asthmatic 
patients were randomly divided into 2 groups, 
receiving therapy for 2 months: 
- Group (A): 20 patients received leukotriene 
modifiers (Montelukast, 5 mg/day). 
- Group (B): 20 patients received inhaled 
corticosteroids (Fluticasone, 200µg/ day). 
 
Laboratory Investigations 
 Total leucocytic count was obtained and the 
absolute eosinophilic count (AEC) was then 
calculated from blood smear (Cell/µL). 
 Serum Ig-E (IU/ml) was measured by the 
quantitative Enzyme Linked Imunosorbent 
Assay (ELISA) (DRG International Inc.USA). 
 Serum Interleukin -5 (IL-5): 
Two venous blood samples were withdrawn 
from each child, one sample on the first visit and 
another sample after two months of regular therapy. 
Serum IL-5 (for all patients before and after therapy 
and controls) was determined by the quantitative 
(ELISA) in accordance with the manufacturer’s 
instructions (IBL International, Germany) and 
calculated (pg/ml). 
 
Pulmonary Function Tests (PFTs)        
PFTs were carried out to all our cases using a 
spirometer (Fukuda Denshi, Spirosift SP5000) on the 
second visit when possible or after 2 weeks later. The 
spirometric parameters included forced vital capacity 
(FVC), forced expiratory volume in the first second 
(FEV1), peak expiratory flow rate (PEFR) and forced 
expiratory flow at 25%-75% (FEF 25-75). All data 
were presented as percentile of normal values. 
 
Statistical Methods 
Data were analyzed using the statistical 
package for social science (SPSS). The t-test was 
used to compare between two groups and ANOVA 
test was used for comparison between more than two 
groups. The following methods were obeyed: 
frequencies distribution, percentage distribution, 
range, mean & standard deviation and correlation co-
efficient (r). P-values less than 0.05 were considered 
statistically significant. The Receiver Operating 
Characteristic curves (ROC curve analysis) were 
applied to assess the effect of therapy on IgE and 
PEFR.   
 
Results 
The demographic data of the studied groups 
were summarized in Table 1. All studied groups were 
matched regarding age, weight, height, and body 
mass index. 
Table 1: Demographic data of groups A, B and control. 
Group B 
(ICS) 
**P-value Controls *P-value 
Group A 
(LTA) 
Item 
10  2 0.144 9  2 0.156 8  2 Age(year) 
32  10 0.903 33  9 0.561 31  15 Weight (Kg) 
136  14 0.438 132  10 0.243 127  16 Height (cm) 
16  1 0.071 18  3 0.310 17  4 BMI (Kg/m
2
 ) 
8.3  3    7  2.7 Asthma duration (years) 
*P-value between Group A and controls;      **P-value between Group B and controls 
 
There was statistically significant difference 
between cases and controls as regards the absolute 
eosinophilic count, IgE, serum IL-5 and pulmonary 
function test parameters at the beginning of the study 
each of  Ig E, eosinophilic count and IL-5 were 
statistically higher in cases compared to control. 
Meanwhile, pulmonary functions were lower (Table 2).  
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Table 2: Comparison between IgE, IL-5, eosinophils and 
pulmonary function tests during acute exacerbation of patients 
(A&B) and controls. 
p-value Controls 
(Mean  SD) 
Total cases (A+B) 
(Mean  SD) 
Item 
 
0.0001 43  17 193  170 IgE (IU/ml) 
0.03 5.5  2.7 13  16 IL-5 (pg/ml) 
0.03 195  100 612  492 Eso (Cell/µL) 
0.0001 94  5 64  5 FVC (%) 
0.0001 101  11 69  6 FEV1 (%) 
0.0001 121  23 80  22 FEF25-75 (%) 
0.0001 104  28 60  14 PEFR (%) 
 
Also, there was significant improvement of Ig 
E, IL-5, eosinophil and pulmonary functions after 
treatment in both groups (A and B). The efficacy of 
both drugs was comparable (Table 3).  
 
Table 3: IL-5, IgE, eosinophils and PFTs during acute 
exacerbation and after treatment in groups A and B. 
 
P-
value 
Group B (ICS) 
 
P-
value 
 
Group A (LTA) 
 
Item 
After 
treatment 
(Mean  
SD) 
Acute 
exacerbation 
(Mean  
SD) 
After 
treatment 
(Mean  
SD) 
Acute 
exacerbation 
(Mean  
SD) 
0.0200 74.6 ± 52.8 119.4 ±118 0.0001 164.6±30.3 265.7 ±185 
IgE 
(IU/ml) 
0.0400 6.5± 4.4 14± 17.0 0.0200 5.7± 4.9 12.5± 15.5 
IL-5 
(pg/ml) 
0.0001 324.1±177.2 534.5±257.5 0.1000 522±258.8 688.6±455.8 
Eo  
(Cell/µL) 
0.0001 78.2 ± 6.6 64.7 ± 5.0 0.0001 78.6 ± 6.4 63.6 ± 6.0 FVC % 
0.0001 85.9 ± 7.6 71.0 ± 6.3 0.0001 85.7 ± 8.0 67.7 ± 5.9 FEV % 
0.0010 107 .5 ±23.7 82.7 ± 21.3 0.0020 100.2±22.5 76.5 ± 23.7 
FEF 25-
75% 
0.0001 80.2 ± 10.8 62.4 ± 13.5 0.0001 74.4 ± 10.0 56.8 ± 13.3 PEF % 
Eso, eosinophils. 
However, there was no correlation between 
IL-5 and each of eosinophilic count, IgE and 
pulmonary function tests (Table 4). 
Table 4: Correlation between IL-5 and IgE, Eoinophils, and 
PFTs during acute exacerbation and after treatment in groups 
A and B. 
Group (B) 
& 
IL-5 
(pg/ml) 
Group (A) 
& 
IL-5 
(pg/ml) 
 
Time of testing 
 
Items 
p r p r 
0.311 0.239 0.858 -0.045 Acute exacerbation 
IgE  (IU/ml) 
0.069 0.415 0.488 -0.175 After treatment 
0.517 0.154 0.092 0.409 Acute exacerbation 
Eso (Cell/µL) 
0.644 0.110 0.423 -0.202 After treatment 
0.308 -0.240 0.226 0.300 Acute exacerbation 
FVC (%) 
0.182 -0.311   After treatment 
0.080 -0.401 0.224 0.302 Acute exacerbation 
FEV1 (%) 
0.476 -0.169   After treatment 
0.523 -0.152 0.707 0.095 Acute exacerbation 
FEF25-75 (%) 
0.474 0.170 0.772 0.074 After treatment 
0.942 0.017 0.371 -0.224 Acute exacerbation 
PEFR (%) 
0.270 0.259 0.692 0.100 After treatment 
 
Table 5 presents the Receiver Operating 
Characteristic curves (ROC curve analysis), showing 
significant difference of IgE and PEFR after treatment 
with leukotriene modifier. 
Table 5: The effect of LT therapy on IgE and PEFR by ROC 
analysis. 
Item IgE PEFR 
Area under the curve 0.85 0.86 
Confidence interval 0.542 – 0.873 0.122 – 0.461 
Statistical significance (p-value)  0.025 0.024 
 
Discussion 
The development of asthma seems to involve 
numerous factors that include genetic, environmental 
and immunological factors [6]. Cytokines play a key 
role in orchestrating the chronic inflammation of 
asthma by recruiting, activating, and promoting the 
survival of multiple inflammatory cells in the 
respiratory tract [7]. Cytokines also direct and modify 
the inflammatory response in asthma and likely 
determine its severity [8]. Eosinophil is considered a 
key effector cell in the pathogenesis of allergic 
inflammation [9]. Increase in eosinophils often 
correlates with greater asthma severity. In our study, 
the absolute eosinophilic count in asthmatic children 
was significantly increased during acute exacerbation 
compared to control group. This was consistent with 
other studies [10]. This can be explained on the basis 
that, in case with atopic asthma, Cysteinyl-
leukotrienes (Cys- Lts) which are potent 
bronchoconstrictors derived mainly from mast cells 
promote eosinophilia [11]. However, after 2 months of 
treatment with either leukotriene modifiers (LTA) or 
inhaled glucocorticosteroids (ICs) reduction in the 
blood eosinophil counts was observed. This result is 
in agreement with other workers [12] who reported 
that Leukotriene receptor antagonists, inhibits Cys-
LTs, cytokines (e.g. IL-4 and IL-5) as well as 
eosinophil activation, leading to reduced eosinophilic 
migration into local tissue.  
IgE plays a central role in the initiation and 
propagation of the inflammatory cascade and thus the 
allergic response [13]. In our study mean serum IgE 
level was significantly elevated in asthmatic children 
during acute exacerbation. This result is in 
accordance with Begum et al [14]. In atopic 
individuals, the IgE receptors result in secretion of 
abnormally high levels of IL4 from mast cells with 
overproduction of IgE antibodies [13]. However, 
significant reduction of IgE was observed after 2 
months of treatment with either LTA or ICs. Similarly, 
Stelmach et al [11] reported significant decrease in 
levels of IgE in asthmatic children received either LTA 
or ICS for 6 months. Both corticosteroids and LTA 
appear to decrease production of IgE from B 
lymphocytes stimulated with IL-4[15]. Allergic 
diseases, including asthma, are characterized by 
inflammation with pronounced infiltration of 
eosinophils and CD4+ T cells. IL-5 is a cytokine that is 
highly specific for eosinophilic inflammation and was 
originally found as ‘T-cell replacing factor’ that is 
secreted from T cells to stimulate antibody production 
from activated B cells [16]. IL-5 seems to be the 
primary cytokine involved in vivo in the production, 
differentiation, maturation and activation of 
eosinophils [9].  
In the present study serum IL-5 level was 
significantly elevated in asthmatic children compared 
to control group. This finding was also reported in 
other studies [17-19].  
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Interleukin-5 has been shown to increase the 
percentage of eosinophils in sputum and augment 
airway hyper responsiveness in asthma and 
antibodies that block IL-5 actions are effective in 
reducing eosinophilic inflammation and airway hyper 
responsiveness in various species [20]. In contrast to 
our results, Pukelsheim et al [21] reported no 
differences between healthy and asthmatic individuals 
in the serum IL-5. 
In our study IL-5 level was significantly 
decreased to reach near control level after LTA or ICS 
treatment for 2 months. Similar to our results, Xie and 
his group [22] reported significant decrease in serum 
IL-5 in asthmatic children after montelukast treatment.  
Riliang et al [23] found that montelukast decreases 
the levels of IL-5 secreted by peripheral blood 
mononuclear cells in patients with asthma. On the 
other hand, non-significant decrease was observed in 
serum IL-5 after 2 months of treatment with inhaled 
corticosteroids. This is in agreement with other reports 
[10, 24] .They reported non- significant reduction of IL-
5 after treatment with inhaled corticosteroids. 
However, this reported decrease of IL-5 may be 
related to the inhibitory role of inhaled corticosteroids 
as an anti- inflammatory drug on Th2 cells with 
subsequent suppression of IL-4 and IL-5 production 
[25].   
The elevation of serum IL-5 and eosinophil 
count was associated with asthma manifestations and 
pulmonary function data. Anti inflammatory therapy 
led to decline in both parameters with subsequent 
improvement in both clinical and pulmonary functions 
data. This proves the direct role of IL-5 in asthma 
inflammatory process. The difference in response to 
either anti inflammatory drugs compared to other 
studies might be related to different genetic 
backgrounds of the studied groups.   
Pulmonary function tests provide valuable 
information about severity of airway obstruction. 
Measurement of lung parameters (FVC%, FEVı%, 
PER% and FEF 25% -75%) by spirometry to assess 
airflow limitation have gained widespread acceptance 
for the use in patients over 5 years of age. In our 
study, all lung parameters were significantly 
decreased in asthmatic children compared to controls. 
There was statistical significant improvement of all 
lung parameters after monteleukst or inhaled steroid 
treatment. In our results, Montelukast when compared 
to inhaled corticosteroid demonstrated similar 
improvements in pulmonary function tests 
improvement. 
This finding agrees with other reports [26, 27] 
who found relative efficacies in the two treatment 
groups. In contrast to our results Garcia et al [28] 
concluded that montelukast was more effective than 
fluticasone in increasing the percentage of asthma 
rescue free days. On the other hand, Meltzer et al [29] 
found that treatment with fluticasone significantly 
improved pulmonary function, asthma symptom 
scores and the percentage of symptom free days 
when compared to montelukast. 
In conclusion, serum IL-5 level seems to have 
an important role in pathogenesis of asthma. Relative 
efficacies of the two treatment groups (ICs & LTA) are 
similar in partly controlled asthmatic children. Both 
treatments led to decline in IL-5, IgE levels and 
eosinophil count.           
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